Fig. 1 · Structure

Documents & Downloads

D-Mannitol

Cat. No. A10323 CAS 69-65-8
D-Mannitol is an osmotic diuretic agent and a weak renal vasodilator.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Mannitol produced osmotic brain water extraction in a rat model with renal regulation suppressed. Brain sodium and chloride content increased alongside water loss, demonstrating a compensatory response under these conditions; the molecular routes of this response were not established. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Microbial Metabolite  
Human Endogenous Metabolite  

D-Mannitol Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of D-Mannitol from 4 published references. In vitro models include Neuro-2a cells overexpressing untagged wild-type human α-synuclein.

D-Mannitol In Vitro Studies

Mannitol affected α-synuclein assembly in a concentration- and endpoint-dependent manner. In a six-day cell-free assay, 0.225 and 0.45 M reduced fibrillation, whereas 0.9 M did not. Lower concentrations did not prevent soluble higher oligomers; 0.225 M increased oligomerization. These results do not support uniform suppression of all aggregate species. [2]

Acute mannitol-induced osmotic stress promoted α-synuclein aggregation in Neuro-2a cells overexpressing untagged human α-synuclein. Aggregation appeared with concentrated stocks of at least 2 M, despite a final equilibrated extracellular concentration of 150 mM. This differs from the prolonged cell-free experiment and limits generalized anti-aggregation claims. [3,2]

Concentration-dependent effects on cell-free α-synuclein assembly

Biochemical assay · 100 μM recombinant α-synuclein in 100 mM Tris, pH 7.4 [2]

After six days, lower tested mannitol concentrations reduced fibrillation, whereas 0.9 M did not. Soluble oligomers responded differently: low concentrations did not prevent their formation, and 0.225 M increased oligomerization. Thus reduced fibril signal does not establish elimination of all aggregates.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fibril formation relative to α-synuclein alonereported result Reduced at 0.225 and 0.45 M (p < 0.005); no significant inhibition at 0.9 M[2]
Soluble tetramers and higher oligomersreported result 0.9 M decreased these species; 0.225 and 0.45 M did not prevent higher oligomers; 0.225 M increased oligomerization[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.225, 0.45 and 0.9 M representative comparisons
Exposure duration
6 days at 37 °C
Method
Incubation with agitation; α-synuclein alone comparator
Vehicle
100 mM Tris, pH 7.4
Reported limits
Mannitol supplier, lot, stereochemical assay and replicate count/error-bar definition for Fig 1 are not specified in the inspected assay description/caption.
Methods and source locations

Compound reported in the paper: Mannitol; Compound label in the paper: Reported as mannitol

Results apply to the reported mannitol preparation and experimental model.

Experimental Procedures: ThT Fluorescence Assay, TEM, Determination of Soluble Oligomer Formation; Results Figs 1–2 and captions

Fibril formation relative to α-synuclein alone: ThT fluorescence, with mannitol fluorescence subtracted; endpoint samples examined by TEM — Fig 1A–E and caption; Results: fibrillation and TEM

Soluble tetramers and higher oligomers: Western blot of soluble fractions; qualitative comparison — Fig 2 and caption; Results: Mannitol Inhibits α-syn Oligomer Formation

Acute mannitol challenge promotes cellular α-synuclein aggregation

Cell-based study · Neuro-2a cells overexpressing untagged wild-type human α-synuclein [3]

In an acute osmotic challenge, aggregation was detected with 2 and 2.5 M mannitol stock solutions despite an equilibrated extracellular concentration of 150 mM. This is a cellular stress result, distinct from prolonged incubation of purified protein.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
High-molecular-weight α-synuclein immunoreactivityreported result Aggregation detected at stock concentrations ≥2 M; mannitol-series ANOVA P < 0.0005[3]

Literature-Reported Treatment Conditions

Treatment concentration
Stock series 0.5, 1, 1.5, 2 and 2.5 M; equilibrated extracellular mannitol 150 mM
Exposure duration
15 min, 48 h after transfection
Method
Concentrated osmolyte added directly to extracellular medium
Vehicle
DMEM with 10% fetal bovine serum
Reported limits
Mannitol supplier/lot and stereochemical characterization are not specified in the inspected treatment methods. Exact mannitol-specific replicate n is not separately provided; general methods state at least two independent experiments per Western blot analysis.
Methods and source locations

Compound reported in the paper: Mannitol; Compound label in the paper: Reported as mannitol

Results apply to the reported mannitol preparation and experimental model.

Results: Hyperosmotic stress induces aggregation of α-syn in cells; Fig 1C,F; Methods: Cell Culture, Osmolyte treatment, Western blot, Statistical analysis; SI Fig S4 and S6G

High-molecular-weight α-synuclein immunoreactivity: Western blot and densitometry; actin loading signal; recombinant fibril positive control and GFP-expressing osmolyte-treated negative control — Fig 1C,F and caption; first Results section; SI Fig S6G

D-Mannitol In Vivo Studies

Animal responses depended on experimental context. A single intraperitoneal mannitol challenge reduced brain water in healthy, functionally nephrectomized female rats but increased brain electrolyte content. In a separate male-rat infarction model, repeated intravenous mannitol increased infarcted hemispheric weight and hemispheric weight asymmetry. These distinct models and endpoints do not establish a universal protective effect. [1,4]

Brain water loss with compensatory electrolyte accumulation

Animal study · Healthy female Sprague–Dawley rats, 9–13 weeks; anesthetized and functionally nephrectomized [1]

A single mannitol challenge reduced brain water at one hour while increasing brain sodium and chloride content. NaCl produced slightly greater water extraction at similar plasma osmolarity. This model suppresses renal regulation and does not model treatment of injured brain.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Brain water contentreported result Mannitol: 3.51 ± 0.02 ml/g dry weight (n = 6); control: 3.79 ± 0.01 (n = 9); p < 0.001[1]
Brain Na+ and Cl− contentreported result Mannitol: Na+ 209 ± 1 and Cl− 182 ± 3 mmol/kg dry weight (n = 6); control: 197 ± 1 and 132 ± 3 (n = 9)[1]
Water extraction relative to equiosmolar NaCl challengereported result Brain water: NaCl 3.46 ± 0.01 ml/g dry weight (n = 9); mannitol less effective, p < 0.05[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single bolus
Treatment course
1 h to endpoint
Vehicle
0.9% w/v NaCl
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Mannitol (n = 6)
7.29 g/kg (2 M); 2 ml/100 g
Isosmolar saline control and hyperosmolar NaCl comparatorReduced brain water with increased Na+ and Cl− content[1]
Isosmolar saline control (n = 9)
0.9% w/v NaCl; 2 ml/100 g
Comparator for mannitolBrain water 3.79 ± 0.01 ml/g dry weight[1]
Hyperosmolar NaCl comparator (n = 9)
1.17 g/kg (1 M); 2 ml/100 g
Isosmolar saline controlBrain water 3.46 ± 0.01 ml/g dry weight[1]
Mannitol (n = 6)
Reported limits: Mannitol arm received no additional inhibitor vehicle. Fig 2 caption notes similar comparisons against either NaCl vehicle group.
Isosmolar saline control (n = 9)
Reported limits: Mannitol arm received no additional inhibitor vehicle. Fig 2 caption notes similar comparisons against either NaCl vehicle group.
Hyperosmolar NaCl comparator (n = 9)
Reported limits: Mannitol arm received no additional inhibitor vehicle. Fig 2 caption notes similar comparisons against either NaCl vehicle group.
Methods and source locations

Compound reported in the paper: Mannitol; Compound label in the paper: Reported as mannitol

Results apply to the reported mannitol preparation and experimental model.

Methods: Animals, Brain water extraction by elevated plasma osmolarity, Table 1, Brain water/electrolyte quantification, Statistical analysis; Results: NaCl is slightly more potent than mannitol; Fig 2a–c and caption

Brain water content: Wet/dry brain weight; mean ± SEM — Results accompanying Fig 2a; Methods Statistical analysis

Brain Na+ and Cl− content: Na+ flame photometry; Cl− colorimetry; mean ± SEM — Fig 2b,c caption; Methods Brain water and electrolyte quantification

Water extraction relative to equiosmolar NaCl challenge: Mean ± SEM; Fig 2 caption specifies one-way ANOVA with Tukey comparisons — Results preceding Fig 2 and section NaCl is slightly more potent than mannitol; Fig 2a caption

Mannitol (n = 6) · Methods: Animals, Brain water extraction by elevated plasma osmolarity, Table 1, Brain water/electrolyte quantification, Statistical analysis; Results: NaCl is slightly more potent than mannitol; Fig 2a–c and caption

Isosmolar saline control (n = 9) · Methods: Animals, Brain water extraction by elevated plasma osmolarity, Table 1, Brain water/electrolyte quantification, Statistical analysis; Results: NaCl is slightly more potent than mannitol; Fig 2a–c and caption

Hyperosmolar NaCl comparator (n = 9) · Methods: Animals, Brain water extraction by elevated plasma osmolarity, Table 1, Brain water/electrolyte quantification, Statistical analysis; Results: NaCl is slightly more potent than mannitol; Fig 2a–c and caption

Repeated mannitol increased infarcted hemispheric weight

Animal study · Adult male Sprague–Dawley rats, 290–320 g; 6 h middle cerebral artery occlusion followed by reperfusion [4]

Repeated mannitol increased ipsilateral hemispheric weight and ipsilateral/contralateral weight ratio versus untreated infarct controls. These are weight-based indices of edema/asymmetry, not direct water-content or intracranial-pressure measurements.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ipsilateral infarcted hemisphere weightreported result Mannitol: 0.77 ± 0.06 g (n = 12); control: 0.68 ± 0.03 g (n = 10); p < 0.01[4]
Ipsilateral/contralateral hemispheric weight ratioreported result Mannitol: 1.23 ± 0.07; control: 1.12 ± 0.05; p < 0.01[4]

Conditions shared by the study groups

Route
Intravenous
Frequency
Every 4 h
Treatment course
Beginning after 6 h occlusion; endpoint 24 h after occlusion ended
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Repeated mannitol (n = 12)
0.8 g/kg per injection (25% solution); six injections, total 4.8 g/kg
Infarcted control group without mannitol (n = 10)Greater infarcted hemispheric weight and IH/CH weight ratio[4]
Repeated mannitol (n = 12)
Reported limits: Vehicle composition and matched sham infusion are not specified in inspected methods.
Methods and source locations

Compound reported in the paper: Mannitol; Compound label in the paper: Reported as mannitol

Results apply to the reported mannitol preparation and experimental model.

Materials and Methods: group assignment, dosing, hemispheric weight and statistics; Table 1; Results: Weight of cerebral hemispheres and IH/CH weight ratio; Fig 3

Ipsilateral infarcted hemisphere weight: Hemispheric weighing; mean ± SD; t-test — Table 1; Results Weight of cerebral hemispheres; Fig 3

Ipsilateral/contralateral hemispheric weight ratio: Weight ratio; mean ± SD; t-test; group n = 12 and 10, respectively — Table 1; Results Weight of cerebral hemispheres and IH/CH weight ratio

Repeated mannitol (n = 12) · Materials and Methods: group assignment, dosing, hemispheric weight and statistics; Table 1; Results: Weight of cerebral hemispheres and IH/CH weight ratio; Fig 3

Specifications

Manufacturer Adooq Bioscience
CAS Number 69-65-8
Formula C6H14O6
Molecular Weight 182.17
Synonyms Diosmol; Manicol; Manita; Manna sugar
SMILES
C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 31 mg/mL (170.16 mM)
Water 31 mg/mL (170.16 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

D-Mannitol Research References

  1. [1] Oernbo EK, Lykke K, Steffensen AB, et al. Cerebral influx of Na+ and Cl- as the osmotherapy-mediated rebound response in rats Fluids and barriers of the CNS (2018). PMID: 30249273 DOI: 10.1186/s12987-018-0111-8 Source material
  2. [2] Shaltiel-Karyo R, Frenkel-Pinter M, Rockenstein E, et al. A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD) The Journal of biological chemistry (2013). PMID: 23637226 DOI: 10.1074/jbc.m112.434787 Source material
  3. [3] Fragniere AMC, Stott SRW, Fazal SV, et al. Hyperosmotic stress induces cell-dependent aggregation of α-synuclein Scientific reports (2019). PMID: 30783136 DOI: 10.1038/s41598-018-38296-7 Source material
  4. [4] Cho J, Kim YH, Han HS, et al. Accumulated mannitol and aggravated cerebral edema in a rat model of middle cerebral artery infarction Journal of Korean Neurosurgical Society (2007). PMID: 19096566 DOI: 10.3340/jkns.2007.42.4.337 Source material

Added to your cart

View Cart Checkout
Loading...